tetano
Editor, Senior Moderator
Rheumatology (Oxford)
. 2022 Oct 25;keac620.
doi: 10.1093/rheumatology/keac620. Online ahead of print.
Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still's disease
Xinyue Hong[SUP] 1 [/SUP], Haoyu Pan[SUP] 1 [/SUP], Yutong Su[SUP] 1 [/SUP], Qiongyi Hu[SUP] 1 [/SUP], Yue Sun[SUP] 1 [/SUP], Honglei Liu[SUP] 1 [/SUP], Xiaobing Cheng[SUP] 1 [/SUP], Junna Ye[SUP] 1 [/SUP], Hui Shi[SUP] 1 [/SUP], Jianfen Meng[SUP] 1 [/SUP], Zhuochao Zhou[SUP] 1 [/SUP], Jinchao Jia[SUP] 1 [/SUP], Tingting Liu[SUP] 1 [/SUP], Mengyan Wang[SUP] 1 [/SUP], Xia Chen[SUP] 1 [/SUP], Yuning Ma[SUP] 1 [/SUP], Zihan Tang[SUP] 1 [/SUP], Fan Wang[SUP] 1 [/SUP], Hao Zhang[SUP] 1 [/SUP], Yijun You[SUP] 1 [/SUP], Dehao Zhu[SUP] 1 [/SUP], Longfang Chen[SUP] 1 [/SUP], Chengde Yang[SUP] 1 [/SUP], Jialin Teng[SUP] 1 [/SUP], Huihui Chi[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: A succession of cases have reported flares of adult-onset Still's disease (AOSD) after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), raising concerns. We aimed to investigate the impact of inactivated SARS-CoV-2 vaccines on disease activity in patients with AOSD.
Methods: We prospectively enrolled clinically inactive AOSD patients visiting the outpatient clinics of our department. The patients received SARS-CoV-2 vaccines (BBIBPCorV, Sinopharm, Beijing, China) voluntarily. The occurrence of relapse in the participants was recorded during the follow-up period and a propensity score matching (PSM) method was used to compare the relapse rates between vaccinated and unvaccinated patients. Localized and systemic symptoms were assessed in the vaccinated patients.
Results: A total of 122 patients with inactive AOSD were included, of which 49.2% (n = 60) voluntarily received the inactivated SARS-CoV-2 vaccine. The relapse rate did not increase significantly in vaccinated patients in comparison with unvaccinated patients (after PSM: 6.8% versus 6.8%), and no relapse occurred within one month after vaccination. No obvious adverse reactions were reported in 75.0% of the participants, and none of the patients reported severe reactions.
Conclusion: Increased disease activity or relapse following vaccination with inactivated SARS-CoV-2 were rare in patients with inactive AOSD. Local and systemic adverse reactions were found to be mild and self-limiting. These safety profiles of inactivated SARS-CoV-2 vaccines in patients with AOSD may assist in eliminating vaccine hesitancy and increase the vaccination rate against SARS-CoV-2.
Keywords: Adult-onset Still’s disease; SARS-CoV-2 vaccine; relapse.
. 2022 Oct 25;keac620.
doi: 10.1093/rheumatology/keac620. Online ahead of print.
Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still's disease
Xinyue Hong[SUP] 1 [/SUP], Haoyu Pan[SUP] 1 [/SUP], Yutong Su[SUP] 1 [/SUP], Qiongyi Hu[SUP] 1 [/SUP], Yue Sun[SUP] 1 [/SUP], Honglei Liu[SUP] 1 [/SUP], Xiaobing Cheng[SUP] 1 [/SUP], Junna Ye[SUP] 1 [/SUP], Hui Shi[SUP] 1 [/SUP], Jianfen Meng[SUP] 1 [/SUP], Zhuochao Zhou[SUP] 1 [/SUP], Jinchao Jia[SUP] 1 [/SUP], Tingting Liu[SUP] 1 [/SUP], Mengyan Wang[SUP] 1 [/SUP], Xia Chen[SUP] 1 [/SUP], Yuning Ma[SUP] 1 [/SUP], Zihan Tang[SUP] 1 [/SUP], Fan Wang[SUP] 1 [/SUP], Hao Zhang[SUP] 1 [/SUP], Yijun You[SUP] 1 [/SUP], Dehao Zhu[SUP] 1 [/SUP], Longfang Chen[SUP] 1 [/SUP], Chengde Yang[SUP] 1 [/SUP], Jialin Teng[SUP] 1 [/SUP], Huihui Chi[SUP] 1 [/SUP]
Affiliations
- PMID: 36282541
- DOI: 10.1093/rheumatology/keac620
Abstract
Objective: A succession of cases have reported flares of adult-onset Still's disease (AOSD) after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), raising concerns. We aimed to investigate the impact of inactivated SARS-CoV-2 vaccines on disease activity in patients with AOSD.
Methods: We prospectively enrolled clinically inactive AOSD patients visiting the outpatient clinics of our department. The patients received SARS-CoV-2 vaccines (BBIBPCorV, Sinopharm, Beijing, China) voluntarily. The occurrence of relapse in the participants was recorded during the follow-up period and a propensity score matching (PSM) method was used to compare the relapse rates between vaccinated and unvaccinated patients. Localized and systemic symptoms were assessed in the vaccinated patients.
Results: A total of 122 patients with inactive AOSD were included, of which 49.2% (n = 60) voluntarily received the inactivated SARS-CoV-2 vaccine. The relapse rate did not increase significantly in vaccinated patients in comparison with unvaccinated patients (after PSM: 6.8% versus 6.8%), and no relapse occurred within one month after vaccination. No obvious adverse reactions were reported in 75.0% of the participants, and none of the patients reported severe reactions.
Conclusion: Increased disease activity or relapse following vaccination with inactivated SARS-CoV-2 were rare in patients with inactive AOSD. Local and systemic adverse reactions were found to be mild and self-limiting. These safety profiles of inactivated SARS-CoV-2 vaccines in patients with AOSD may assist in eliminating vaccine hesitancy and increase the vaccination rate against SARS-CoV-2.
Keywords: Adult-onset Still’s disease; SARS-CoV-2 vaccine; relapse.